Phase I clinical study of a personalized peptide vaccination available for six different human leukocyte antigen (HLA-A2, -A3, -A11, -A24, -A31 and -A33)-positive patients with advanced cancer

Itoh K, Yamada A, Mine T and Noguchi M: Recent advances in cancer vaccines: an overview. Jpn J Clin Oncol. 39:73–80. 2009. View Article : Google Scholar : PubMed/NCBI

Itoh K and Yamada A: Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci. 97:970–976. 2006. View Article : Google Scholar : PubMed/NCBI

Finn OJ: Cancer immunology. N Engl J Med. 358:2704–2715. 2008. View Article : Google Scholar : PubMed/NCBI

Parker KC, Bednarek MA and Cokigan JE: Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol. 152:163–175. 1994.PubMed/NCBI

Rammensee HG, Friede T and Stevanoviic S: MHC ligands and peptide motifs: first listing. Immunogenetics. 41:178–228. 1995. View Article : Google Scholar : PubMed/NCBI

Imanishi T, Akazawa T, Kimura A, Tokunaga K and Gojobori T: Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. HLA 1991, Vol. 1. Tsuji K, Aizawa M and Sasazuki T: Oxford Scientific Publications; Oxford: pp. 1065–1220. 1992

Sidney J, Grey HM, Southwood S, Celis E, Wentworth PA, del Guercio MF, Kubo RT, Chesnut RW and Sette A: Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. Hum Immunol. 45:79–93. 1996. View Article : Google Scholar : PubMed/NCBI

Noguchi M, Kobayashi K, Suetsugu N, Tomiyasu K, Suekane S, Yamada A, Itoh K and Noda S: Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate. 57:80–92. 2003. View Article : Google Scholar

Noguchi M, Itoh K, Suekane S, Yao A, Suetsugu N, Katagiri K, Yamada A, Yamana H and Noda S: Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer. Cancer Sci. 95:77–84. 2004. View Article : Google Scholar : PubMed/NCBI

Noguchi M, Itoh K, Suekane S, Morinaga A, Sukehiro A, Suetsugu N, Katagiri K, Yamada A and Noda S: Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer. Prostate. 60:32–45. 2004. View Article : Google Scholar

Takedatsu H, Shichijo S, Katagiri K, Sawamizu H, Sata M and Itoh K: Identification of peptide vaccine candidates sharing among HLA-A3⁺, -A11⁺, -A31⁺, and -A33⁺ cancer patients. Clin Cancer Res. 10:1112–1120. 2004. View Article : Google Scholar : PubMed/NCBI

Minami T, Matsueda S, Takedatsu H, Tanaka M, Noguchi M, Uemura H, Itoh K and Harada M: Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles. Cancer Immunol Immunother. 56:689–698. 2007. View Article : Google Scholar

Naito M, Komohara Y, Ishihara Y, Noguchi M, Yamashita Y, Shirakusa T, Yamada A, Itoh K and Harada M: Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles. Br J Cancer. 97:1648–1654. 2007. View Article : Google Scholar : PubMed/NCBI

Hida N, Maeda Y, Katagiri K, Takasu H, Harada M and Itoh K: A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation. Cancer Immunol Immunother. 51:219–228. 2002. View Article : Google Scholar : PubMed/NCBI

Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL and Wiley DC: The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature. 329:512–518. 1987. View Article : Google Scholar : PubMed/NCBI

Wheatley AP, Bolland DJ, Hewitt JE, Dewar JC and Hall IP: Identification of the autoantigen SART-1 as a candidate gene for the development of atopy. Hum Mol Genet. 11:2143–2146. 2002. View Article : Google Scholar : PubMed/NCBI

Terasaki Y, Shichijo S, Niu Y, Komatsu N, Noguchi M, Todo S and Itoh K: An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles. Cancer Immunol Immunother. 58:1877–1885. 2009. View Article : Google Scholar : PubMed/NCBI

Mohamed ER, Naito M, Terasaki Y, Niu Y, Gohara S, Komatsu N, Shichijo S, Itoh K and Noguchi M: Capability of SART3(109-118) peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles. Int J Oncol. 34:529–536. 2009.PubMed/NCBI